We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Gedeon Richter

News List

Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval pharmatimes
July 22, 2021
Myovant Sciences and Gedeon Richter have gained an approval from the European Commission (EC) for its uterine fibroids treatment Ryeqo, the company announced 20th.
UK launch for Vagirux pharmatimes
December 08, 2020
Gedeon Richter has announced the UK launch of Vagirux (estradiol hemihydrate) for the treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women with or without a uterus.
New transdermal HRT spray rolled out in the UK pharmatimes
April 16, 2020
Gedeon Richter has launched its new hormone replace therapy (HRT) Lenzetto (estradiol spray) in the UK, offering post-menopausal women an alternative treatment option for symptoms of oestrogen deficiency.
Allergan, Gedeon Richter Receive FDA Approval for Expanded Use of VRAYLAR® for Bipolar Depression americanpharmaceuticalreview
May 29, 2019
Allergan and Gedeon Richter announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR® (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar